eli lilly tirzepatide fda approval Lilly's gained in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Zepbound (tirzepatide) FDA Approval History

A useful framing from a clinical perspective: NAD+ helps patients feel better faster, while Sermorelin helps them function better overall

If sweating occurs, investigating underlying causes and contributing factors is essential for appropriate management

Phentermine is also known to interact with serotonin-modulating medications, which creates additional complexity if you're taking antidepressants or anxiety medications alongside weight loss therapy

Tirzepatide clinical trials have shown an average weight loss of 20-22% of body weight a clinically meaningful result for patients with obesity or weight-related health conditions

The SUMMIT trial demonstrated that tirzepatide significantly reduced the risk of HF hospitalisation or an urgent visit requiring intravenous diuretics